-
Product Insights
NewNet Present Value Model: Elevation Oncology Inc’s EO-3021
Empower your strategies with our Net Present Value Model: Elevation Oncology Inc's EO-3021 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EOS-984 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EOS-984 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EOS-984 in Solid Tumor Drug Details: EOS-984 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-2040 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-2040 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-2040 in Colorectal Cancer Drug Details: EO-2040 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-2002 in Corneal Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-2002 in Corneal Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-2002 in Corneal Edema Drug Details: EO-2002 is under development for...
-
Innovation Ranking
Innovation Ranking – EO Technics Co Ltd
EO Technics Co Ltd (EOTechnics) is a technology company that manufactures and markets laser processing equipment. It provides equipment for use in manufacturing of semiconductor, liquid crystal displays and printed circuit boards. The company offers products in marking, grooving, dicing, cutting, drilling, notching, annealing, and cleaning facilities. EOTechnics also provides equipment such as semiconductor, display, PCB and macro; lasers including fiber laser, DPSS and DDL. It serves automobile, machine, and other sectors. The company operates through its offices located in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-2463 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-2463 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-2463 in Marginal Zone B-cell Lymphoma Drug Details: EO-2463...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tindupepimut in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tindupepimut in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tindupepimut in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Tindupepimut...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belrestotug in Recurrent Head And Neck...
-
Sector Analysis
NewEthylene Market Analysis and Forecast by Products, Capacity Additions, Top Countries and Active and Upcoming Projects to 2030
Ethylene Market Report Overview The ethylene market has shown robust and consistent growth and will grow at a CAGR of more than 2% during 2024-2030. The following are some of the key highlights of the ethylene market: Ethylene is a key petrochemical used for producing important commodities such as polyethylene, ethylbenzene, and ethylene oxide which, in turn, are widely used in packaging, automotive, and construction materials. Asia emerges as the leading regional ethylene market sector with China accounting for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-2463 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-2463 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-2463 in Marginal Zone B-cell Lymphoma Drug Details: EO-2463 is...